Latest Breaking News On - Generic drug repurposing - Page 1 : comparemela.com
Leveraging Pharmacoeconomics and Advance Market Commitments to Reduce Healthcare Expenditures
fas.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fas.org Daily Mail and Mail on Sunday newspapers.
Cholesterol Drug in Use Since 1975 Could Prevent COVID-19 Lung Damage, Study Shows
vidanewspaper.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vidanewspaper.com Daily Mail and Mail on Sunday newspapers.
Dec 30, 2020
WorldComments Off on Cholesterol Drug in Use Since 1975 Could Prevent COVID-19 Lung Damage, Study Shows
JERUSALEM Researchers believe a well-established drug could prevent lung damage in COVID-19 patients, potentially reducing the severity and mortality rate of the illness.
A study started by the Hebrew University of Jerusalem in July has since demonstrated that the coronavirus inhibits the effective breakdown of fat in lungs, resulting in a buildup that can negatively impact patients. Initial data presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 showed that 1,500 Israel-based coronavirus patients recovered quickly after taking a regimen of fibrates, or drugs designed to lower triglycerides (fats) in the blood.
Existing Drug Fenofibrate Proves Its Efficacy Against COVID-19 by Karishma Abhishek on December 24, 2020 at 2:12 PM
Lung damage in COVID-19 patients can be treated using an existing drug Fenofibrate as presented at SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University.
The study resuming its course in July 2020 shows that
SARS-CoV-2 virus is capable of inhibiting the effective breakdown of fat within the lungs, as demonstrated by initial lab-based results and new data from 1,500 Israel-based Corona patients.
The Repurposed Drug
‘Devastating lung damage caused in COVID-19 patients can be treated using an existing drug Fenofibrate (Tricor). The drug reduces the build up of fats in the lung tissues thereby slowing down the damage caused by the virus.’
Early clinical data demonstrates the efficacy of existing drug in treating COVID-19
In what has the potential to significantly change how Corona patients are being treated and the severity of the disease, research spearheaded at Jerusalem s Hebrew University gathered early clinical evidence demonstrating the efficacy of an existing drug in treating COVID-19.
The study was presented at the recent SPARK Conference on Generic Drug Repurposing for COVID-19 by Professor Yaakov Nahmias, Director of the Center for Bioengineering at Hebrew University. Nahmias applied a well-established existing drug to address the buildup of fats in human lung cells caused by the SARS-CoV-2 virus. Initial lab-based results and new data from 1,500 Israel-based Corona patients have been extremely promising and clinical studies are scheduled to begin this week at Barzilai Hospital in Ashkelon, Israel, joining other clinical centers across the United States, South America and Europe.
vimarsana © 2020. All Rights Reserved.